Related Experiment Video

Updated: Jun 26, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Recent advances of novel targeted therapy in non-small cell lung cancer

Jed A Katzel1, Michael P Fanucchi, Zujun Li

  • 1Department of Hematology and Oncology, Saint Vincent's Hospital, Manhattan and New York Medical College, Valhalla, NY, USA. jkatzel@aptiumoncology.com

Journal of Hematology & Oncology
|January 23, 2009
PubMed

Insights

Targeted therapies are improving outcomes for advanced non-small cell lung cancer (NSCLC). New agents targeting cancer cells offer hope for personalized lung cancer treatment, with over 500 agents in development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer remains the leading cause of cancer-related mortality globally.
  • Advances in cancer biology have identified new therapeutic targets in neoplastic cells.
  • Targeted therapies represent a significant development in cancer treatment.

Purpose of the Study:

  • To review the current landscape of targeted therapies for advanced non-small cell lung cancer (NSCLC).
  • To highlight approved and emerging targeted agents in NSCLC treatment.
  • To discuss the future prospects of molecularly targeted therapies in lung cancer.

Main Methods:

  • Review of FDA-approved targeted agents for advanced NSCLC.
  • Discussion of emerging targeted therapies, including cetuximab.
  • Overview of the pipeline of molecularly targeted agents in development.

Main Results:

  • Two targeted agents, erlotinib (EGFR TKI) and bevacizumab (antiangiogenic), are FDA-approved for advanced NSCLC.
  • Cetuximab shows promise in enhancing survival when combined with chemotherapy for advanced NSCLC.
  • Over 500 molecularly targeted agents are currently under development for various cancers.

Conclusions:

  • Targeted therapies have significantly advanced the treatment of advanced NSCLC.
  • The development of novel targeted agents offers a bright future for personalized lung cancer therapy.
  • Continued research into molecular targets promises improved outcomes for individual patients.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...